Deploying next-generation adjuvants to enhance protection of a group A streptococcal vaccine candidate [ 2019 - ]

Research Grant

Researchers: Prof Mark Walker (Principal investigator) ,  Dr Nicole Moreland ,  Prof Guido Silvestri ,  Prof Victor Nizet

Brief description Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (GSK) leading to human trials and the development of a safe group A streptococcal vaccine for human use.

Funding Amount $1,052,324.00

Funding Scheme Development Grants

Notes Development Grant